How Is The Cigna Group’s Stock Performance Compared to Other Healthcare Plans

How Is The Cigna Group’s Stock Performance Compared to Other Healthcare Plans

Wed, September 2, 2026 at 2:12 PM GMT+3 2 min read

• CI +1.18%

Evernorth Health Services segments, it provides healthcare and related services to more than 185 million customer relationships across over 30 markets and jurisdictions. It has a market capitalization of $73 billion.

Companies worth $10 billion to $200 billion are generally described as "large-cap stocks," and The Cigna Group definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance within the healthcare plans industry. Its large market presence, broad revenue base, more than 540 U.S. patents, and use of AI and machine learning strengthen its competitive position and support operational efficiency.

More News from Barchart

Despite its notable strengths, CI has slipped 10.3% from its 52-week high of $315.47, reached on October 3, 2025. Over the past three months, CI stock has climbed 3.2%, underperforming the State Street SPDR S&P Health Care Services ETF (XHS), which has gained 17.7% over the same period.

Shares of CI have gained 2.8% year-to-date but plunged 5.9% over the past 52 weeks, significantly underperforming XHS, which has gained 26% year-to-date and delivered a 35.5% return over the past year.

CI has dipped below its 50-day moving average since late July and its 200-day moving average since early August, indicating a downward trend.

Cigna has struggled to keep pace with the broader market as its shrinking customer base raises concerns about product and sales momentum. Its customer count has declined 8.1% annually on average over the past two years, suggesting the company has lost deals and renewals amid increasing competition or market saturation.

On July 30, CI shares dropped about 3% after reporting its Q2 results. Its adjusted income from operations per share of $7.78 surpassed Wall Street expectations of $7.58, while the company's revenue of $71.67 billion beat Wall Street forecasts of $71.43 billion.

In the competitive Healthcare Plans industry, top rival UnitedHealth Group Incorporated (UNH) has shown resilience and considerably outperformed CI, gaining 20.1% year-to-date and 27.9% over the past 52 weeks.

Wall Street analysts are moderately bullish on CI's prospects. The stock has a consensus "Moderate Buy" rating from 23 analysts, and the mean price target of $340.65 represents a 20.3% premium to its current price.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com